TYK2 and B-cell chronic lymphocytic leukemia: Treatment of IFN-treated CLL cells with JAK2 or TYK2 inhibitors did not completely abolish cell survival and upregulation of STAT3 and Mcl-1, suggesting the involvement of another tyrosine kinase in STAT3 activation.